On July 31, | Citibank published a report to conduct a 30-day negative catalyst observation on Fosun Pharmaceuticals (2196.HK). It is expected that under the high base brought about by COVID-19 mRNA vaccines and test packs in the same period last year, revenue for the first half of this year is expected to fall short of expectations. Furthermore, the profits of the Indian pharmaceutical company Gland Pharma will also decline. The bank gave Fosun Pharma a a “buy” rating, with a target price of HK$40.